SOTAC PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of SOTAC PHARMACEUTICALS have increased by 5.92% YoY .
The Earnings Per Share (EPS) of SOTAC PHARMACEUTICALS has decreased by -77.32 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SOTAC PHARMACEUTICALS Last 5 Annual Financial Results
[NSE : SOTAC]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|
| Revenues | ₹77 Cr | ₹73 Cr | ₹49 Cr | ₹29 Cr |
| Expenses | ₹70 Cr | ₹67 Cr | ₹47 Cr | ₹27 Cr |
| Operating Profit (Excl OI) | ₹7.32 Cr | ₹6.17 Cr | ₹1.46 Cr | ₹1.87 Cr |
| Other Income | ₹0.35 Cr | ₹0.22 Cr | ₹0.11 Cr | ₹0.22 Cr |
| Interest | ₹2.04 Cr | ₹0.57 Cr | ₹1.03 Cr | ₹0.33 Cr |
| Depreciation | ₹2.28 Cr | ₹1.13 Cr | ₹2.59 Cr | ₹1.40 Cr |
| Profit Before Tax | ₹3.93 Cr | ₹4.70 Cr | ₹-2.06 Cr | ₹0.36 Cr |
| Profit After Tax | ₹2.29 Cr | ₹2.88 Cr | ₹-2.37 Cr | ₹0.09 Cr |
| Consolidated Net Profit | ₹2.29 Cr | ₹2.88 Cr | ₹-2.37 Cr | ₹0.09 Cr |
| Earnings Per Share (Rs) | ₹2.84 | ₹12.52 | ₹-10.28 | ₹0.38 |
| PAT Margin (%) | 2.95 | 3.94 | -4.84 | 0.31 |
| ROE(%) | 27.53 | 63.16 | -85.23 | 2.86 |
| ROCE(%) | 21.50 | 31.31 | -5.71 | 4.18 |
| Total Debt/Equity(x) | 2.21 | 1.12 | 6.87 | 4.40 |
Key Financials |
||
| Market Cap | : | ₹ 127.7 Cr |
| Revenue (TTM) | : | ₹ 90.2 Cr |
| Net Profit(TTM) | : | ₹ 3.0 Cr |
| EPS (TTM) | : | ₹ 2.7 |
| P/E (TTM) | : | 42.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SOTAC PHARMACEUTICALS | -6.2% | -5.7% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | -1.8% | -2.9% | 52.3% |
| CIPLA | -1.4% | 4.5% | 57% |
| DR REDDYS LABORATORIES | 0.2% | -5.3% | 32.4% |
| ZYDUS LIFESCIENCES | -4.9% | 7.3% | 105.8% |
| DIVIS LABORATORIES | 7% | 10.3% | 26.7% |
| MANKIND PHARMA | 1.5% | -11.5% | 58.9% |
| TORRENT PHARMACEUTICALS | 1.8% | 0.7% | 59.5% |
| LUPIN | -2.2% | -4.1% | 105.4% |
SOTAC PHARMACEUTICALS Revenues
[NSE : SOTAC]
| Y-o-Y | 5.92 % |
| 5 Yr CAGR | 39.40 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹77 Cr | 5.92 | |
| Mar2022 | ₹73 Cr | 49.77 | |
| Mar2021 | ₹49 Cr | 70.76 | |
| Mar2020 | ₹29 Cr | - | |
SOTAC PHARMACEUTICALS Operating Profit
[NSE : SOTAC]
| Y-o-Y | 18.52 % |
| 5 Yr CAGR | 57.66 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹7.32 Cr | 18.52 | |
| Mar2022 | ₹6.17 Cr | 323.97 | |
| Mar2021 | ₹1.46 Cr | -22.01 | |
| Mar2020 | ₹1.87 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 11.85 % |
| 5 Yr CAGR | 13.07 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 9.44% | 11.85 | |
| Mar2022 | 8.44% | 183.22 | |
| Mar2021 | 2.98% | -54.36 | |
| Mar2020 | 6.53% | - | |
SOTAC PHARMACEUTICALS Profit After Tax
[NSE : SOTAC]
| Y-o-Y | -20.60 % |
| 5 Yr CAGR | 196.16 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹2.29 Cr | -20.60 | |
| Mar2022 | ₹2.88 Cr | Positive | |
| Mar2021 | ₹-2.37 Cr | Negative | |
| Mar2020 | ₹0.09 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -25.13 % |
| 5 Yr CAGR | 111.91 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 2.95 % | -25.13 | |
| Mar2022 | 3.94 % | Positive | |
| Mar2021 | -4.84 % | Negative | |
| Mar2020 | 0.31 % | - | |
SOTAC PHARMACEUTICALS Earnings Per Share (EPS)
[NSE : SOTAC]
| Y-o-Y | -77.32 % |
| 5 Yr CAGR | 95.51 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹2.84 | -77.32 | |
| Mar2022 | ₹13 | Positive | |
| Mar2021 | ₹-10 | Negative | |
| Mar2020 | ₹0.38 | - | |
SOTAC PHARMACEUTICALS Return on Capital Employed (ROCE)
[NSE : SOTAC]
| Y-o-Y | -31.33 % |
| 5 Yr CAGR | 72.62 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 21.5% | -31.33 | |
| Mar2022 | 31.31% | Positive | |
| Mar2021 | -5.71% | Negative | |
| Mar2020 | 4.18% | - | |
SOTAC PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹115.0 |
| Current MarketCap | : | ₹ 127.7 Cr |
| Updated EOD on | : | May 30,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOTAC PHARMACEUTICALS | -6.2% |
-5.7% |
|
| SENSEX | -2% |
-1.1% |
19.4% |
SOTAC PHARMACEUTICALS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about SOTAC PHARMACEUTICALS Financials
How the annual revenues of SOTAC PHARMACEUTICALS have changed ?
The Revenues of SOTAC PHARMACEUTICALS have increased by 5.92% YoY .
How the Earnings per Share (EPS) of SOTAC PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of SOTAC PHARMACEUTICALS has decreased by -77.32 % YoY .
Check out Intrinsic Value of Peers of SOTAC PHARMACEUTICALS
Compare Stock Analytics of Peers of SOTAC PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
